17,110 Shares in Danaher Corporation $DHR Bought by Granite Islands Private Wealth LLC

Granite Islands Private Wealth LLC bought a new position in Danaher Corporation (NYSE:DHR) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 17,110 shares of the conglomerate’s stock, valued at approximately $3,791,000. Danaher makes up approximately 2.2% of Granite Islands Private Wealth LLC’s investment portfolio, making the stock its 12th biggest holding.

Other large investors have also recently bought and sold shares of the company. Patriot Investment Management Group Inc. bought a new stake in shares of Danaher during the 3rd quarter valued at about $944,000. NFSG Corp grew its holdings in shares of Danaher by 488.8% during the third quarter. NFSG Corp now owns 3,091 shares of the conglomerate’s stock worth $685,000 after purchasing an additional 2,566 shares in the last quarter. Detalus Advisors LLC grew its holdings in shares of Danaher by 975.1% during the third quarter. Detalus Advisors LLC now owns 12,708 shares of the conglomerate’s stock worth $2,815,000 after purchasing an additional 11,526 shares in the last quarter. Murphy Middleton Hinkle & Parker Inc. purchased a new position in shares of Danaher during the third quarter worth about $6,985,000. Finally, Walser Wealth Management Company A Ltd Liability Co bought a new position in shares of Danaher in the third quarter worth approximately $1,459,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

DHR opened at $231.52 on Friday. The stock has a market capitalization of $162.76 billion, a P/E ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The stock has a 50-day moving average price of $213.55 and a 200-day moving average price of $195.74.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the previous year, the company posted $0.77 EPS. Danaher’s quarterly revenue was up 5.5% compared to the same quarter last year. Equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on DHR shares. Stifel Nicolaus lowered their target price on shares of Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Morgan Stanley boosted their price target on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research note on Monday. Wells Fargo & Company cut their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Finally, Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.